BB Biotech AG (BIONZ.XC)
Cboe UK · CHF · Healthcare · Biotechnology
CHF 50.40 (+1.41%) as of
Key statistics
- Market cap
- 2.78B
- P/E (TTM)
- 22.01
- EPS (TTM)
- 2.29
- 52-week range
- 35.95 – 50.40
- Beta
- 0.67
- Revenue (TTM)
- 1.06B
- Profit margin
- 127.31%
- Volume
- 5.68k
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Küsnacht, Switzerland
- Employees
- 10
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.